Coherus BioSciences to Present at Upcoming Investor Conferences in March
Rhea-AI Impact
Rhea-AI Sentiment
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March.
- 43rd Annual Cowen Health Care Conference on Tuesday, March 7th at 2:10 p.m. ET
- Barclays 2023 Global Healthcare Conference on Tuesday, March 14th at 4:05 p.m. ET
Audio webcasts of these presentations will be available on the investors’ page of the Coherus website at http://investors.coherus.com. Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. Each webcast will be archived on the Coherus website for 30 days.
Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
IR@coherus.com
Coherus BioSciences, Inc.
NASDAQ:CHRS
CHRS Rankings
CHRS Latest News
Apr 24, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 8, 2024
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS Stock Data
233.81M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
REDWOOD CITY
About CHRS
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp